MORF · Categories · Earnings
MORF - Earnings announcements
Morphic Holding Inc. (MORF) earnings announcements - real-time wire coverage filtered to Earnings only.
Recent Earnings for MORF
- Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023-Presented positive EMERALD-1 Phase 2a data for MORF-057 in patients with moderate to severe ulcerative colitis at UEG Week 2023- -Continued enrollment on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis- -Ended third quarter with $725.1 million in cash, cash equivalents, and marketable securities providing runway into the second half of 2027- WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the third quarter 2023. "Morphic presented a compre
- Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data SetWALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss the complete results from the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The positive topline results from EMERALD-1 were reported in April of this year and the full data set will be presented at the upcoming UEG Week 2023. The webcast and call will be held at 7:45 AM Eastern Time on October 12, 2023. A live webcast of the call will be available via
- Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in the Robarts Histopathology Index (RHI) Score- -MORF-057 achieves 25.7% clinical remission by Modified Mayo Clinic Score (mMCS)- -MORF-057 generally well tolerated with no safety signal observed- -MORF-057 achieves saturation of α4β7 receptor and demonstrates changes in α4β7 lymphocyte subsets that are consistent with Phase 1 MORF-057 data - -Conference call and webcast to discuss results today at 8:00 AM ET- WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin
- Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023WALTHAM, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ:MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced it will host a webcast and conference call to discuss topline results from the main cohort of the open-label EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis. The webcast and conference call will be held at 8:00 AM Eastern Time on April 25, 2023. A live webcast of the call will be available on the Investors section of Morphic's website, at www.morphictx.com. An archived replay will be available on the company's website f